Clinical Trials Directory

Trials / Completed

CompletedNCT03184740

Physical Performance and Analgesic Effects of tDCS in Primary Dysmenorrhea

Physical Performance and Analgesic Effects of tDCS in Primary Dysmenorrhea: A Randomized, Double Blind Clinical Trial

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
20 (actual)
Sponsor
Universidade Federal do Rio Grande do Norte · Academic / Other
Sex
Female
Age
18 Years – 60 Years
Healthy volunteers
Not accepted

Summary

Technological advances and non-invasive techniques to modulate brain function have been developed, including transcranial Direct Current Stimulation (tDCS). Basically, electrodes are placed on the brain regions to stimulate or inhibit it. Subsequently, a continuous electrical current (0.4-2 mA) is imposed, for a period of 3-20 minutes, to modify cortical excitability. Few are the research groups that work on the topic of primary dysmenorrhea and the use of tDCS as the focus of study. Preliminary studies associated the use of tDCS with pain reduction, but the outcomes of physical and behavioral function needs further investigation.

Conditions

Interventions

TypeNameDescription
DEVICEActive Transcranial Direct Current StimulationFor electrode placement, the criteria used by the 10/20 electroencephalography system will be obeyed and the electrodes will be positioned over Primary motor cortex, C3 area for the anode and Fp2 (contralateral supraorbital area) for the cathode electrode. A constant current of 2mA will be applied for 20 minutes.
DEVICESham Transcranial Direct Current StimulationFor electrode placement, the criteria used by the 10/20 electroencephalography system will be obeyed and the electrodes will be positioned over primary motor cortex, C3 area for the anode and Fp2 (contralateral supraorbital area) for the cathode electrode, but the stimulator will be turned off after 30 seconds of stimulation.

Timeline

Start date
2017-06-01
Primary completion
2017-07-31
Completion
2017-08-31
First posted
2017-06-14
Last updated
2017-09-12

Locations

1 site across 1 country: Brazil

Source: ClinicalTrials.gov record NCT03184740. Inclusion in this directory is not an endorsement.